# US 2010/0168036 A1 · Growth factor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168036 A1
- Document ID: US20100168036A1
- Status: Published application
- Kind: A1
- Application number: 12/595,482
- Filed: 2008-03-27
- Published: 2010-07-01
- Earliest claimed: 2007-04-12
- Assignees: University of Bradford
- Inventors: Jason Gill; Paul Loadman; Rob Falconer; Laurence Patterson; Jennifer Atkinson; Mike Bibby
- Web page: https://patentgrep.com/patent/US20100168036A1

## CPC

- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/65: Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/08: Vasodilators for multiple indications
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 29/02: without antiinflammatory effect
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 7/06: having 5 to 11 amino acids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.

## Claims

### Claim 1

A compound, or pharmaceutically acceptable salt thereof, comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site.

### Claim 2 (depends on 1)

A compound according to claim 1 wherein the compound is of formula (I)
X-Y (I)
wherein
X is a vascular disrupting agent (VDA); and
Y is a matrix metalloproteinase (MMP) proteolytic cleavage site.

### Claim at position 3

3-21. (canceled)

### Claim 22 (depends on 1)

A compound according to claim 1 wherein the compound is of formula (II)
X-Y-c (II)
wherein X is a vascular disrupting agent (VDA);
Y is a matrix metalloproteinase (MMP) proteolytic cleavage site and
c is a capping group.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

A compound according to claim 1 wherein the compound is of formula (III)
X-a-Y (III)
wherein X is a vascular disrupting agent (VDA);
Y is a matrix metalloproteinase (MMP) proteolytic cleavage site; and
a is a linker directly or indirectly associated with X.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

A compound according to claim 1 wherein the compound is of formula (IV)
X-a-Y-c (IV)
wherein X is a vascular disrupting agent (VDA);
a is a linker directly or indirectly associated with X;
Y is a matrix metalloproteinase (MMP) proteolytic cleavage site; and
c is a capping group.

### Claim 27 (depends on 1)

A compound according to claim 1 wherein the compound is of formula (V)
X-Y-b-c (V)
wherein
X is a vascular disrupting agent (VDA);
Y is a matrix metalloproteinase (MMP) proteolytic cleavage site;
b is a spacer group directly or indirectly linked to Y; and
c is a capping group.

### Claim 28

(canceled)

### Claim 29 (depends on 1)

A compound according to claim 1 wherein the compound is of formula (VI)
X-a-Y-b-c (VI)
wherein a is a linker directly or indirectly associated with X;
X is a vascular disrupting agent (VDA);
Y is a matrix metalloproteinase (MMP) proteolytic cleavage site;
b is a spacer group directly or indirectly linked to Y; and
c is a capping group.

### Claim 30

A compound, or pharmaceutically acceptable salt thereof, of formula (VII)
X-Y-Z (VII)
wherein X; is a vascular disrupting agent (VDA);
Y is a matrix metalloproteinase (MMP) proteolytic cleavage site; and
Z is an anti-cancer agent.

### Claim at position 13

31-33. (canceled)

### Claim 34 (depends on 2)

A process for preparing the compound of claim 2, the process comprising the steps of
i) providing a solid support attached to X
ii) optionally attaching a linker a to the C or N terminal of X
iii) attaching amino acid residues step-wise to the C or N terminal of X, or the linker attached to X in (ii), to provide the peptide sequence Y containing the MMP proteolytic cleavage sequence;
iii) optionally attaching a capping group c to the respective C or N terminal of Y.

### Claim 35

Use of a MMP proteolytic cleavage site in the site specific activation of a VDA.

### Claim 36 (depends on 1)

A compound, or pharmaceutically acceptable salt thereof, according to claim 1 for use in medicine.

### Claim 37 (depends on 1)

A pharmaceutical formulation comprising a compound according to claim 1 and at least one additional pharmaceutically acceptable excipient, diluent or carrier.

### Claim 38

(canceled)

### Claim 39 (depends on 1)

A method to treat a disease or condition associated with tissue expressing an MMP in a subject comprising administering an effective amount of the compound of claim 1 or a formulation comprising a compound according to claim 1 and at least one additional pharmaceutically acceptable excipient, diluent, or carrier.

### Claim 40

(canceled)

### Claim 41 (depends on 1)

Use of a compound according to claim 1 in the manufacture of a medicament to treat cancer.

### Claim 42 (depends on 1)

A method to treat an inflammatory disorder in a subject comprising administering an effective amount of a compound according to claim 1.

### Claim 43 (depends on 1)

Use of a compound according to claim 1 in the manufacture of a medicament to treat an inflammatory disorder.

### Claim 44 (depends on 1)

A method to treat heart failure in a subject comprising administering an effective amount of a compound according to claim 1.

### Claim 45 (depends on 1)

Use of a compound according to claim 1 for the manufacture of a medicament to treat heart failure.

### Claim 46 (depends on 1)

A method to treat a wound in a subject comprising administering an effective amount of a compound according to claim 1.

### Claim 47 (depends on 1)

Use of a compound according to claim 1 for the manufacture of a medicament to treat a wound.
